CHAPTER 14: Advanced Strategies in UTI and Pyelonephritis Management for Nephrologists

Specialist chapter for nephrologists

Urinary tract infection is a clinical syndrome, not a positive urine culture in isolation. The central decisions are to identify whether symptoms are localized to the bladder or reflect systemic infection, estimate the risk of treatment failure or resistant organisms, obtain cultures when they will change management, start empiric therapy proportionate to illness severity, and correct obstruction or other sources of persistence. In patients with CKD, transplantation, stones, catheters, neurogenic bladder, pregnancy, immunosuppression, or recurrent infection, antimicrobial selection must be integrated with renal dosing, drug toxicity, interactions, and source control.

This chapter uses the modern distinction between localized UTI, usually cystitis without systemic illness, and systemic UTI, which may include pyelonephritis, prostatitis, bacteremia, or sepsis. Risk factors do not by themselves prove infection, but they influence diagnostic testing, empiric therapy, imaging, and follow-up.[1] [3]

Learning objectives

By the end of this chapter, the learner should be able to distinguish localized urinary symptoms from systemic UTI; interpret urinalysis and urine cultures in context; recognize asymptomatic bacteriuria and avoid inappropriate treatment; construct empiric therapy using illness severity, resistance risk, patient-specific factors, and local antibiograms; identify obstruction, abscess, emphysematous infection, prostatitis, and catheter-related infection; dose and monitor antimicrobials in CKD and dialysis; manage pregnancy, transplant, neurogenic bladder, and recurrent UTI; and apply antimicrobial-stewardship principles to IV-to-oral transition and duration.

14.1 Definitions and classification

A localized UTI is a syndrome of new dysuria, frequency, urgency, suprapubic pressure, or urethral symptoms without signs suggesting systemic infection. A systemic UTI includes fever or hypothermia, rigors, hypotension, tachycardia, delirium attributable to infection, flank pain or costovertebral-angle tenderness, acute kidney injury, bacteremia, or other evidence of upper-tract or systemic involvement. Localized and systemic symptoms may coexist.[1] [3]

Risk factors that may increase the likelihood of severe disease, treatment failure, resistant organisms, or an anatomic source include urinary obstruction, stones, hydronephrosis, urinary retention, neurogenic bladder, indwelling or intermittent catheters, recent instrumentation, prior resistant isolates, recent antibiotics, diabetes, advanced CKD, transplant immunosuppression, pregnancy, frailty, and prostatic involvement. Male sex should prompt consideration of prostate disease and obstruction but should not be treated as an automatic substitute for clinical classification.

14.2 Epidemiology, microbiology, and pathogenesis

Most community-acquired infections are caused by uropathogenic Escherichia coli, but the organism distribution changes with age, healthcare exposure, obstruction, catheters, stones, recent antibiotics, and immunosuppression. Klebsiella, Proteus, Enterobacterales with ESBL production, Enterococcus, Pseudomonas, Staphylococcus saprophyticus, and Candida may be encountered in selected settings. A prior urine culture is one of the most useful predictors of the next infecting organism and its susceptibility profile.

Ascending infection remains the dominant pathogenesis. Uropathogenic E. coli use adhesins and fimbriae to resist washout and interact with urothelial receptors. Intracellular bacterial communities and mucosal reservoirs may contribute to recurrence, although recurrent symptoms can also reflect vaginitis, urethral syndrome, pelvic-floor dysfunction, bladder pain syndrome, stones, malignancy, or persistent infection from an anatomic source.

Hematogenous spread is less common but should be considered in bacteremia, Staphylococcus aureus bacteriuria, candidemia, severe immunosuppression, or an endovascular source. In nephrology practice, infection may precipitate AKI through sepsis-associated tubular injury, hypovolemia, obstruction, interstitial nephritis, rhabdomyolysis, or nephrotoxic therapy.

14.3 Clinical assessment and red flags

A focused history should establish symptom onset, localization, fever trajectory, rigors, flank or pelvic pain, vomiting, pregnancy possibility, sexual and gynecologic symptoms, prior cultures, antibiotics, resistant organisms, catheter and instrumentation history, stone disease, obstruction, urinary retention, transplant status, dialysis status, and medication allergies. Review nephrotoxic and interacting drugs, including NSAIDs, RAAS blockers during sepsis-related volume depletion, metformin in severe AKI, anticoagulants, QT-prolonging drugs, and immunosuppressants.

Immediate escalation is warranted for hypotension, altered mental status, persistent tachycardia, lactate elevation, rapidly worsening kidney function, anuria or oliguria with suspected obstruction, severe pain, inability to take oral medication, pregnancy with systemic symptoms, transplant pyelonephritis, neutropenia, or concern for emphysematous infection or abscess.

A patient with fever and flank pain may have pyelonephritis, but alternative diagnoses include obstructing stone, renal infarction, papillary necrosis, renal vein thrombosis, abscess, appendicitis, diverticulitis, pelvic inflammatory disease, cholecystitis, or pneumonia. Absence of dysuria does not exclude upper-tract infection, and pyuria does not prove that urinary symptoms are caused by infection.

Urinalysis and microscopy

Pyuria supports urinary inflammation but is not specific for bacterial infection. Nitrite positivity supports nitrate-reducing organisms but a negative result does not exclude UTI, particularly with low bladder dwell time, dilute urine, non-nitrate-reducing organisms, or recent antibiotics. Leukocyte esterase may be positive in infection and noninfectious inflammation. Hematuria may occur with infection, but persistent hematuria after treatment requires an appropriate hematuria evaluation. Casts, dysmorphic red cells, or significant proteinuria should raise concern for glomerular disease rather than uncomplicated cystitis.

Urine culture

Culture is important when systemic infection is suspected, during pregnancy, in recurrent culture-confirmed UTI, in many men with febrile infection, in transplant recipients, when resistant organisms are likely, after recent antibiotics, with obstruction or catheterization, and when symptoms persist or recur. In typical first-episode localized cystitis in a healthy nonpregnant woman, empiric treatment may be reasonable without culture when local practice and resistance patterns support it. A contaminated specimen should be repeated; a catheterized specimen may be useful when clean-catch results are unreliable.

Culture interpretation requires attention to colony count, specimen quality, mixed growth, pyuria, symptoms, and prior antibiotics. A positive culture without symptoms is asymptomatic bacteriuria, not automatically infection.

Blood cultures and laboratory testing

Obtain blood cultures in sepsis, hemodynamic instability, severe systemic illness, immunosuppression, transplant pyelonephritis, suspected endovascular infection, or when bacteremia would change duration or disposition. Check CBC, electrolytes, creatinine, bicarbonate, glucose, lactate when indicated, and drug-specific monitoring parameters. In CKD, use an appropriate kidney-function estimate for dosing and reassess dosing as creatinine changes.

14.5 Imaging and source control

Imaging is not routinely required for uncomplicated localized cystitis. It is indicated early when obstruction, stone, hydronephrosis, abscess, emphysematous infection, renal infarction, severe AKI, unusual organisms, recurrent systemic infection, or failure to improve is suspected. Ultrasound can identify hydronephrosis and some stones without radiation. CT is more sensitive for stones, gas, abscess, and complicated anatomy; contrast decisions should balance diagnostic value against kidney function and the urgency of the clinical question.

An infected obstructed system is a urologic emergency. Antibiotics alone may fail when infected urine cannot drain. Urgent decompression by ureteral stent or nephrostomy, culture of drained material, and coordinated urology–infectious-disease care may be required. Source control also includes catheter removal or replacement, relief of retention, drainage of abscess, removal of infected foreign material when feasible, and treatment of a prostatic or perinephric focus.

14.6 Asymptomatic bacteriuria

Asymptomatic bacteriuria is bacteriuria without local urinary symptoms or systemic signs attributable to infection. Pyuria may be present and does not convert asymptomatic bacteriuria into symptomatic UTI. Screening and treatment should generally be avoided in healthy nonpregnant adults, older adults, diabetes, chronic catheters, neurogenic bladder, and most stable transplant populations, because treatment rarely improves outcomes and increases resistance and adverse effects.[5]

Screen and treat in pregnancy according to obstetric and local guidance, and before selected invasive urologic procedures in which mucosal trauma and bacteremia are expected. In older adults with bacteriuria and delirium or a fall but no local urinary symptoms, fever, or hemodynamic instability, evaluate other causes and observe rather than reflexively prescribing antibiotics. A change in urine odor, cloudy urine, or pyuria alone is not an indication for treatment.

14.7 Antimicrobial selection in systemic UTI

The 2025 IDSA complicated-UTI guideline recommends a four-step empiric assessment: severity of illness, resistance risk, patient-specific considerations, and the local antibiogram when the patient is septic.[1] Obtain cultures before antibiotics when this does not delay resuscitation. Use the narrowest effective empiric regimen compatible with severity and resistance risk, then de-escalate promptly when results return.

Potential empiric classes include third-generation cephalosporins, piperacillin–tazobactam, fluoroquinolones when appropriate, carbapenems for selected ESBL-risk or severe resistant infections, and newer agents guided by local susceptibility and infectious-disease consultation. No class should be selected by diagnosis label alone. Aminoglycosides may provide activity but require careful nephrotoxicity and therapeutic-monitoring considerations in CKD.

IV-to-oral switch and treatment duration

When the patient is hemodynamically stable, improving, able to absorb oral medication, and an active oral option is available, IV-to-oral transition reduces line complications and broad-spectrum exposure. The duration should reflect syndrome, response, source control, bacteremia, prostatitis, abscess, obstruction, immune status, and the active agent. Many clinically improving systemic UTIs can be treated with shorter courses than the traditional 7–14 days, while inadequate source control or deep infection may require longer therapy.[1]

14.8 Localized cystitis

For typical localized cystitis in a nonpregnant woman without major resistance or anatomic risk, first-line oral therapy commonly includes nitrofurantoin, TMP-SMX when susceptibility and local resistance support its use, or fosfomycin. Selection must incorporate kidney function, pregnancy, allergy, prior cultures, interactions, and local resistance. Nitrofurantoin achieves high urine concentrations but is not appropriate for pyelonephritis, bacteremia, or suspected renal tissue infection. Fosfomycin is also not a general treatment for systemic UTI.

Fluoroquinolones should not be routine first-line therapy for localized cystitis because of collateral damage, resistance, and potentially serious adverse effects. Beta-lactams may be used when appropriate but often have lower efficacy or require longer courses than preferred first-line agents. Phenazopyridine may provide short-term dysuria relief in selected patients but does not treat infection and requires renal-function and duration cautions.

14.9 Pyelonephritis and systemic UTI

Assess disposition using hemodynamics, renal function, comorbidity, oral tolerance, social support, pregnancy, transplant status, resistance risk, and obstruction. Stable patients who can take oral medication may be treated as outpatients with a culture-informed oral agent. When an oral fluoroquinolone is used, local resistance and any recommended initial parenteral dose should be considered. TMP-SMX is appropriate when the isolate is susceptible; empiric use without susceptibility may be unreliable. Oral beta-lactams are alternatives in selected cases but require attention to efficacy and duration.

Hospitalize patients with sepsis, shock, severe AKI, vomiting, inability to take oral therapy, pregnancy with systemic illness, immunocompromise, transplant pyelonephritis, suspected obstruction, uncontrolled pain, or failure of outpatient therapy. Start timely empiric IV therapy, obtain source cultures, evaluate for obstruction, and narrow promptly.

14.10 Catheter-associated UTI and neurogenic bladder

Do not diagnose catheter-associated UTI from bacteriuria or pyuria alone. Evaluate new fever, rigors, flank pain, pelvic discomfort, hemodynamic instability, or other attributable symptoms while considering nonurinary sources. If a catheter has been in place long enough for biofilm formation, replace it when clinically indicated and obtain a culture from the new catheter rather than the old drainage bag. Avoid routine catheter changes solely to sterilize urine.

In neurogenic bladder, symptoms may be atypical and baseline bacteriuria is common. Establish an individualized symptom pattern, bladder-emptying strategy, residual-volume assessment, catheterization technique, and culture interpretation plan. Repeated antibiotics for asymptomatic bacteriuria promote resistance and do not correct the underlying voiding dysfunction.

Pregnancy

Pregnancy changes the risk tolerance for bacteriuria and systemic infection. Screen for asymptomatic bacteriuria early in pregnancy and treat confirmed bacteriuria with pregnancy-compatible therapy. Febrile UTI in pregnancy requires obstetric assessment, culture, monitoring for sepsis and preterm complications, and usually initial inpatient or closely supervised parenteral therapy depending on severity.

Kidney transplant

Transplant recipients may present atypically, and the consequences of pyelonephritis include graft dysfunction, bacteremia, and interactions with calcineurin inhibitors or mTOR inhibitors. Coordinate antimicrobial choice with transplant teams, review prior cultures and prophylaxis, monitor tacrolimus or cyclosporine levels when interactions are possible, and distinguish asymptomatic bacteriuria from symptomatic graft infection. Early imaging is appropriate when obstruction, collection, vascular complications, or graft dysfunction is suspected.

CKD and dialysis

Adjust renally cleared antimicrobials as eGFR changes and account for dialysis clearance and post-dialysis dosing. Avoid nephrotoxic combinations when alternatives exist. TMP-SMX may cause hyperkalemia and creatinine changes; aminoglycosides can cause tubular toxicity; vancomycin requires exposure monitoring; fluoroquinolones may prolong QT and cause dysglycemia or neurotoxicity. During sepsis, reassess both underdosing and accumulation because the apparent kidney function may change rapidly.

14.12 Recurrent UTI in women

Recurrent UTI should be based on recurrent symptomatic episodes with evidence of pyuria and uropathogenic bacteria. The 2025 AUA/CUA/SUFU guideline recommends urinalysis and culture with each symptomatic episode in recurrent UTI, avoids routine surveillance cultures when asymptomatic, and does not recommend routine cystoscopy or upper-tract imaging in the index patient without atypical features.[2]

First address modifiable factors: spermicide exposure, incomplete emptying, prolapse, stones, atrophic vaginitis, catheter use, diabetes control, and unnecessary antibiotics. Behavioral measures should be individualized. Increased water intake may help women with low baseline intake, but forced hydration is not a universal prescription and is unsafe in some patients.

For peri- or postmenopausal women without contraindication, vaginal estrogen reduces recurrence risk. Cranberry can be offered as an option, with counseling that product formulations and proanthocyanidin content vary. Methenamine hippurate is an antibiotic-sparing option in selected patients. D-mannose alone should not be presented as reliably effective. If recurrences persist after culture confirmation and shared decision-making, postcoital, patient-initiated, or continuous low-dose antibiotic prophylaxis may be considered with periodic reassessment.

Do not perform a test-of-cure culture in an asymptomatic patient routinely. Repeat culture when symptoms persist, recur rapidly, or fail to respond; if symptoms continue despite microbiological cure, evaluate alternative diagnoses including vaginitis, urethral pain syndrome, bladder pain syndrome, pelvic-floor dysfunction, stones, and malignancy.

14.13 Prevention and antimicrobial stewardship

Stewardship begins before the prescription: do not culture without a clinical question, do not treat colonization, use prior culture data, select the narrowest effective therapy, dose for kidney function, reassess at 48–72 hours, de-escalate when possible, and document the intended duration and stop date. A prolonged antibiotic course does not substitute for drainage of an obstructed infected system.

Prevention also includes catheter avoidance, aseptic insertion and maintenance, early removal, bladder-emptying optimization, stone management, treatment of obstruction, and coordinated care for recurrent or resistant infection. Education should emphasize red flags and the distinction between urinary colonization and infection.

Summary

UTI management is syndrome-based. Localized cystitis is generally treated with targeted oral therapy, while systemic UTI requires cultures, severity assessment, resistance-risk evaluation, patient-specific dosing, and consideration of imaging and source control. Asymptomatic bacteriuria should not be treated in most populations. An infected obstruction, abscess, emphysematous infection, catheter biofilm, or prostatitis can make apparently appropriate antibiotics fail. In CKD, transplant, pregnancy, and dialysis, the treatment plan must integrate renal dosing, interactions, toxicity, and specialist coordination. Recurrent UTI prevention relies on culture-confirmed episodes, vaginal estrogen when appropriate, selected nonantibiotic strategies, and antibiotic prophylaxis only after shared decision-making.

Clinical pearls

1. A positive culture is not synonymous with UTI; symptoms and systemic signs determine the syndrome.
2. Male sex alone does not define treatment complexity; assess prostate, obstruction, retention, and systemic illness.
3. Nitrofurantoin and fosfomycin are lower-tract drugs and should not be used for pyelonephritis.
4. In systemic UTI, use severity, resistance risk, patient factors, and the antibiogram when septic to select empiric therapy.
5. An infected obstructed collecting system requires drainage as well as antibiotics.
6. Pyuria may accompany asymptomatic bacteriuria, stones, catheters, interstitial nephritis, and glomerular disease.
7. Older adults with bacteriuria and delirium but no urinary or systemic signs should be evaluated for other causes rather than reflexively treated.
8. Recurrent UTI requires documented symptomatic episodes with inflammation and uropathogenic bacteria, not repeated screening cultures.
9. In CKD, antimicrobial dosing must be revisited during AKI, dialysis, and recovery.
10. Persistent symptoms after a negative or treated culture should trigger a differential diagnosis rather than automatic antibiotic escalation.

Suggested website figures

Figure 14.1: Localized versus systemic UTI pathway. Begin with symptoms, then branch to cystitis without systemic illness versus systemic infection with fever, rigors, flank pain, hypotension, AKI, or sepsis. Add a parallel risk-factor branch for obstruction, stones, catheters, pregnancy, transplant, CKD, and resistant organisms.

Figure 14.2: Complicated UTI empiric-treatment framework. Display the four IDSA domains: severity, resistance risk, patient-specific factors, and antibiogram in sepsis. Follow with culture review, source control, IV-to-oral transition, and duration reassessment.

Figure 14.3: Recurrent UTI prevention pathway. Show confirmation of symptomatic culture-positive episodes, evaluation for atypical features, vaginal estrogen, cranberry or methenamine options, and selective prophylactic antibiotics.

Question 1 — Positive urine culture without symptoms

An 82-year-old nursing-home resident has a urine culture growing E. coli at 10⁵ CFU/mL. She has no dysuria, fever, flank pain, hypotension, or new urinary symptoms. What is the best management?

Answer: Do not prescribe antibiotics; assess other causes only if a nonlocalizing symptom such as delirium is present, and monitor clinically.

Rationale: This is asymptomatic bacteriuria. Treating colonization promotes resistance and adverse effects without improving outcomes in most older adults.

Question 2 — Pyelonephritis with obstruction

A patient with fever, flank pain, AKI, and hydronephrosis has a distal ureteral stone. What is the priority?

Answer: Start timely empiric antibiotics and arrange urgent urinary decompression with urology.

Rationale: Antibiotics may not sterilize an infected obstructed system. Drainage is source control and can be lifesaving.

Question 3 — Nitrofurantoin error

A patient with fever, vomiting, CVA tenderness, and pyuria is prescribed nitrofurantoin. What is the major concern?

Answer: Nitrofurantoin does not provide reliable renal-tissue or systemic concentrations for pyelonephritis.

Rationale: Use a culture-informed systemic regimen and assess disposition, resistance risk, and obstruction.

Question 4 — Empiric therapy in septic cUTI

Which set of factors should guide empiric antibiotic choice in septic complicated UTI?

Answer: Illness severity, resistance risk, patient-specific factors, and the local antibiogram.

Rationale: The 2025 IDSA guideline emphasizes this four-step approach before choosing among broad empiric options.

Question 5 — Recurrent UTI evaluation

A 44-year-old woman reports four episodes of “UTI” in one year, but only one had pyuria and a positive culture. What is the next best step?

Answer: Obtain urinalysis and culture with symptomatic episodes and evaluate alternative causes before labeling all episodes recurrent bacterial UTI.

Rationale: Recurrent UTI requires documented inflammation and uropathogenic bacteria associated with symptoms.

References

1. Trautner BW, et al. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections. IDSA guideline.
2. Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline, 2025 amendment. AUA guideline.
3. European Association of Urology. Guidelines on Urological Infections, current guideline. EAU guideline.
4. Nicolle LE, et al. IDSA 2019 Clinical Practice Guideline Update for the Management of Asymptomatic Bacteriuria. IDSA guideline.
5. IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. IDSA AMR guidance.
6. Centers for Disease Control and Prevention. Catheter-Associated Urinary Tract Infection Prevention. CDC guidance.

Educational notice: This chapter supports clinical education and does not replace local antibiograms, product labeling, infectious-disease or urology consultation, or individualized patient assessment.